22 search results for: remission

Is 1 year an appropriate timeframe for deciding if a patient has achieved <b>remission</b> in CRSwNP?
expert video

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

Rhinology
Prof. Hellings and Prof. Corso explore the time frame to assess if the patient with CRSwNP has achieved remission
View more
Clinical <b>Remission</b> as a Goal in Asthma Clinical Practice
expert video

Clinical Remission as a Goal in Asthma Clinical Practice

Pulmonology
Profs. Alberto Papi and Ian Pavord discuss clinical remission as a goal in asthma clinical practice beyond symptom control
View more
ADVENT On Air | <b>Remission</b> in CRSwNP
Podcast

ADVENT On Air | Remission in CRSwNP

Rhinology
Prof. Peter Hellings and Dr. Stella Lee discuss the concept of remission for patients with chronic rhinosinusitis with nasal polyps.
View more
IRS-ISIAN 2024 | Emerging Expert Definitions of <b>Remission</b> in CRSwNP
expert video

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

Rhinology
Prof. Peter Hellings highlights the EPOS/EUFOREA 2024 definition of remission and calls for an elevation of treatment goals in CRSwNP.
View more
ADVENT On Air | The Road Ahead: Achieving <b>Remission</b> for ​Patients With Asthma
Podcast

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

Pulmonology
Join Professors Klaus Rabe and Ian Pavord as they discuss the importance of on-treatment clinical remission as a goal in asthma management.
View more
IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease <b>Remission</b>
expert video

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

Rhinology
Prof. Peter Hellings and Prof. Eugenio De Corso discuss viewpoints on the emerging definitions of disease remission in CRSwNP.
View more
What treatments may be needed to achieve <b>remission</b>? And In what percentage of patients could <b>remission</b> be a target?
expert video

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

Rhinology
Prof. Hellings and Prof. Corso highlight that disease severity plays a key role in rate and control of remission in CRS.
View more
ADVENT On Air | What Is the Future Outlook for <b>Remission</b> in Pediatric Severe Asthma?
Podcast

ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?

Pulmonology
Join Drs. Len Bacharier and Sharon Dell as they highlight the natural course of pediatric asthma progression over time.
View more
Can Chronic Rhinosinusitis With Nasal Polyps be Considered in <b>Remission</b> if the Patient has an Impaired Sense of Smell?
expert video

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

Rhinology
Dr. Backer discusses assessing remission in CRSwNP by evaluating the patient's sense of smell in this video clip from the EAACI 2024 symposium.
View more
IRS-ISIAN 2024 | <b>Remission</b> in CRSwNP: A Real-World Perspective
expert video

IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective

Rhinology
Prof. Eugenio De Corso describes the importance of real-world evidence for understanding the prospects of remission and the emerging evidence of biologic effectiveness for patients with CRSwNP.
View more
The Impact of Advanced Systemic Therapies on Disease Control and Potential <b>Remission</b> in Atopic Dermatitis
expert video

The Impact of Advanced Systemic Therapies on Disease Control and Potential Remission in Atopic Dermatitis

Dermatology
Exploring the concept ​of disease modification relating to therapeutic interventions with targeted systemic therapies in atopic dermatitis​.
View more
ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD
Podcast

ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

Dermatology
Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention and disease modification may impact disease course.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Costa RicaChange country/region